CELL AND GENE THERAPY

Enara Bio Relocates to The Oxford Science Park's Newest Facility to Expand R&D Capabilities

Enara Bio | December 09, 2020

Enara Bio, a biotechnology organization utilizing its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver focused on cancer immunotherapies, announces its extension and move to the new Bellhouse Building at The Oxford Science Park. Enara Bio's move from the Oxford BioEscalator to one of the UK's biggest biomedical advancement habitats is in anticipation of its future development and desire to change malignancy care. The devoted exploration office will empower the organization to quicken the preclinical improvement of its lead MR1-targeting on T-cell therapy program while continuing to drive the disclosure of novel disease antigens and TCRs for immunotherapy.

The move, which will see the organization possess more than 5,000 sq. ft of office and laboratory space in the Bellhouse Building, is a key milestone in Enara Bio's development and improvement. The reason fabricated office will empower Enara Bio to unite key faculty with world-driving abilities in bioinformatics, immunopeptidomics, cell therapy measure development, and immunology to discover and develop novel TCR-based immunotherapies.

Spotlight

Vicki Symington (Society for General Microbiology) and John Schollar (National Centre for Biotechnology Education, Reading) demonstrate how to produce a pour plate.

Spotlight

Vicki Symington (Society for General Microbiology) and John Schollar (National Centre for Biotechnology Education, Reading) demonstrate how to produce a pour plate.

Related News

CELL AND GENE THERAPY

BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psoriasis and inflammatory bowel disease. BGB-23339 is a potent, highly selective, investigational TYK2 inhibitor targeting the regulatory pseudokinase (JH2) domain. “Discovered and developed by BeiGene, BGB-23339 is a highly selective, potent, allosteric TYK2 inhibitor that has shown promising activity in preclinical evaluation. Building on our proven track record in oncology, BeiGene is expanding its clinical focus to discover new modalities and platforms in areas of high unmet need, including inflammation and immunology, to bring innovative, impactful medicines to patients.” Lai Wang, Ph.D., Global Head of R&D at BeiGene The first-in-human Phase 1 trial (NCT05093270) is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of BGB-23339. The trial is expected to enroll up to 115 healthy volunteers in Australia and/or China. In addition to its broad portfolio focused on hematological malignancies and solid tumors, BeiGene is applying its research excellence and clinical expertise to address inflammation and immunology, an area of high unmet medical need. BeiGene’s internally developed, highly selective next-generation BTK inhibitor BRUKINSA® (zanubrutinib) is currently being evaluated in a Phase 2 trial in patients with active proliferative lupus nephritis. About BGB-23339 BGB-23339 is a potent, highly selective, allosteric, investigational tyrosine kinase 2 (TYK2) inhibitor discovered and being developed by BeiGene. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders. Designed to target the regulatory pseudokinase (JH2) domain on TYK2, BGB-23339 has demonstrated strong selectivity in preclinical studies with potent inhibition of interleukin (IL)-12, IL-23, and Type 1 interferons (IFNs)—pro-inflammatory cytokines that play a determinant role in the induction of inflammation. BGB-23339 is currently being evaluated in a Phase 1 clinical study. About BeiGene BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding plans for the Phase 1 trial and development of BGB-23339, the potential for BGB-23339 to address unmet medical needs, BeiGene’s plan to expand its clinical focus to discover new modalities and platforms in areas of high unmet need, including inflammation and immunology, and BeiGene’s plans, commitments, aspirations and goals under “About BeiGene”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on the BeiGene’s clinical development, regulatory, commercial, and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Read More

MEDICAL

Mission Bio Announced the Launch of First Single-Cell Genomics Solid Tumor Solution on the Tapestri Platform

Mission Bio | March 30, 2022

Mission Bio, Inc., a pioneer in high-throughput single-cell DNA and multi-omics research, announced the commercial availability of the Tapestri Solution for Solid Tumor Research. On the Tapestri Platform, this new end-to-end single-cell DNA sequencing process comprises a nuclei isolation prep technique, pre-designed research panels for breast cancer and glioblastoma multiforme, and an enhanced single-cell copy number variation (CNV) bioinformatic analysis tool. Mission Bio currently covers solid tumors in addition to hematologic malignancies, where Tapestri is widely used to study tumor heterogeneity and gain new insights into the clonal variety and architecture driving disease progression, biomarkers, and therapeutic management. Recent high-profile research studies utilizing custom Tapestri assays for breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma have demonstrated the utility of high-resolution tools for assessing solid tumor heterogeneity and clonal evolution, which contribute to disease onset, progression, and relapse. However, bulk next-generation sequencing technologies cannot offer the cell-by-cell mutational data required to detect disease-causing biological drivers — they are confined to population-level average metrics and lack information on clonal diversity. Tapestri quantifies DNA mutations at the individual cell level in thousands of cells simultaneously, simultaneously detecting SNVs, indels, and CNVs, conclusively identifying variant zygosity and mutational co-occurrence recognizing unusual cell populations. As a result, researchers studying solid tumors may now make use of a comprehensive workflow designed for the Tapestri Platform, which includes the following: Sample preparation assistance with an enhanced nuclei isolation process for both fresh and frozen samples New study panels for breast cancer and glioblastoma were meticulously selected to contain hotspot genes, copy number variants, and chromosomal arm aneuploidies linked with each illness. Additionally, users may create custom panels that target specific human or mouse genome regions. Enhanced capacity for CNV bioinformatics analysis with the development of a new visualization tool (in collaboration with Mission Bio's Field Application Scientist team). This integrated workflow approach has the potential to significantly advance our knowledge of disease progression and enable the development of more specific medicines. The commercial introduction of Mission Bio's Tapestri Solution for Solid Tumor Research demonstrates the company's ongoing commitment to allowing more precise cancer research using single-cell DNA sequencing. In addition, mission Bio has announced the establishment of its first Center of Excellence for solid tumor single-cell DNA profiling at Memorial Sloan Kettering Cancer Center (MSKCC). The impressive results already seen from our early work with solid tumor researchers helped guide the development of these new workflows and underscored our commitment to providing unique and indispensable tools for solid tumor researchers. Just as Tapestri has been an invaluable tool for hematologic malignancy researchers, we're confident that our research panel pair, new prep protocol, and improved bioinformatics analysis capabilities will demonstrate the platform's value in solid tumors." CEO of Mission Bio, Yan Zhang, Ph.D., said.

Read More

MEDICAL

Stramsen Biotech, Inc. to Fund Next Phases of Clinical Trials and Additional Medicine Discovery Research

Stramsen Biotech, Inc | December 17, 2020

Stramsen Biotech, Inc, a professional group of medication researchers from the Houston, Texas territory comprises of scientists who devote their lives each day to investigating and exploring both the cycles and logical instruments hidden the world we live in today. Colleagues have gotten a few honors and awards for research ventures, with a significant number of their activities and distributions accessible upon demand. Individuals incorporate PhD and University level professors who specialize in chemistry, medication and different biotechnology research projects. This group of experienced researchers has been included widely in clinical examination for more than 20 years. Stramsen Biotech, Inc has more than six drug/medicine candidates currently in early-stage clinical trials. Two drug/medicine candidates have demonstrated promising outcomes in early clinical preliminaries for treatment of HIV/AIDS. A third drug applicant has additionally demonstrated promising outcomes in early clinical preliminaries for treatment of numerous kinds of wounds and cuts, including diabetic injuries. A fourth medication applicant shows promising outcomes in early clinical preliminaries for treating the basic Flu and Covid-19. The fifth outstanding medication competitor, focusing on ongoing and advance stage malignant growths, has additionally indicated promising outcomes in early clinical preliminaries. Finally, a 6th applicant as an immunization shows promising clinical preliminary outcomes for Newcastle disease, a infection of domestic poultry and other winged creature species with the virulent Newcastle disease virus (NDV).

Read More